Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
NCT ID: NCT01478269
Last Updated: 2011-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1927 participants
OBSERVATIONAL
2009-05-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases of aggressive B-cell lymphoma
Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Any stage of disease.
3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
4. Age at least 18 years.
5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
6. Availability of data on clinical involvement, laboratory, treatment and follow up.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Massimo Federico, MD
Role: STUDY_DIRECTOR
Oncologia II Azienda Ospedaliera Universitaria di Modena
Stefano Luminari, MD
Role: PRINCIPAL_INVESTIGATOR
Oncologia II Azienda Ospedaliera Universitaria di Modena
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hemocentro-Unicamp
Campinas, , Brazil
Centro Medico
Santa Isabel, , Brazil
Centro Paulista de Oncologia
São Paulo, , Brazil
Santa Casa Medical School
São Paulo, , Brazil
Clinica Ematologica Policlinico Carreggi
Florence, Firenze, Italy
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
Milan, Milano, Italy
A.O.SS. Biagio, Antonio e Cesare Arrigo
Alessandria, , Italy
Centro di riferimento Oncologico Oncologia Medica A
Aviano (Pordenone), , Italy
USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo
Bergamo, , Italy
Presidio Ospedaliero A.Perrino - Divisione di Ematologia
Brindisi, , Italy
U.O. di Oncologia Ospedale di Circolo di Busto Arsizio
Busto Arsizio, , Italy
Ospedale Civile
Camposanpiero (PD), , Italy
A.O.Pugliese Ciaccio Diviisone di Ematologia
Catanzaro, , Italy
Presidio Ospedaliero Annunziata U.O.C. di Ematologia
Cosenza, , Italy
Ematologia 1 Ospedale S. Martino
Genova, , Italy
Oncologia Medica B e C IST Genova
Genova, , Italy
Ospedale Felettino
La Spezia, , Italy
Ospedale Madonna delle grazie U.O. Ematologia
Matera, , Italy
A O Papardo
Messina, , Italy
Azienda Ospedaliero Universitaria Policlinico Gaetano Martino
Messina, , Italy
Oncologia Medica 3 Istituto Nazionale dei Tumori di Milano
Milan, , Italy
Osp. San Carlo Borromeo Divisione di Oncologia Medica
Milan, , Italy
Ospedale Maggiore IRCCS-Dipartimento di Ematologia
Milan, , Italy
Centro Oncologico Modenese
Modena, , Italy
A.O. Maggiore della Carità S.C.D.U. Ematologia
Novara, , Italy
A.O. di Padova Divisione di Oncologia Medica
Padua, , Italy
Casa di cura La Maddalena Unita' di Ematologia
Palermo, , Italy
Div. di Ematologia e TMO AOU Policlinico Giaccone di Palermo
Palermo, , Italy
A O Universitaria di Parma
Parma, , Italy
Ospedale Civile G.da Saliceto - UOA Ematologia
Piacenza, , Italy
Azienda Ospedaliero Universitaria Pisana U.O. Ematologia
Pisa, , Italy
AO Bianchi Melacrino Morelli UO Ematologia
Reggio Calabria, , Italy
AO Arcispedale S.Maria Nuova Ematologia
Reggio Emilia, , Italy
Ospedale Oncologico regionale CROB
Rionero in Vulture (PZ), , Italy
Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza
Roma, , Italy
Policlinico A. Gemelli Università Cattolica del Sacro Cuore
Roma, , Italy
Clinica Humanitas
Rozzano (MI), , Italy
A.O.San Giovanni Battista
Torino, , Italy
U.O. Oncologia Azienda ULSS7 P.O. di Vittorio Veneto
Vittorio Veneto, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIL_ProDLBCL
Identifier Type: -
Identifier Source: org_study_id